On December 17, 2024, the US stock market closed with mixed results. The Dow Jones Industrial Average fell by 0.61%, the NASDAQ Composite decreased by 0.32%, and the S&P 500 declined by 0.39%.

In terms of industry sectors, the new energy vehicle sector saw significant gains, with Tesla ($TSLA$) rising by 3.64%, NIO ($NIO$) up by 2.71%, and XPeng ($XPEV$) increasing by 3.63%. The cannabis sector also performed well, with Aurora Cannabis ($ACB$) up by 4.20% and Tilray ($TLRY$) increasing by 3.33%. On the other hand, the semiconductor sector experienced a decline, with NVIDIA ($NVDA$) down by 1.22% and Broadcom ($AVGO$) falling by 3.91%.

Tesla ($TSLA$) saw a significant increase of 3.64%, reaching a new all-time high with a market capitalization exceeding $1.5 trillion. This surge was driven by positive earnings guidance and strong market performance.

NVIDIA ($NVDA$) dropped by 1.22% due to concerns over a slowdown in AI spending and rumors of overheating issues with its AI systems. Despite announcing a collaboration with Verizon to develop AI applications on Verizon's 5G private network, the stock continued to decline.

Amazon ($AMZN$) fell by 0.76% following news of an investigation by Italian authorities into tax and labor practices, including allegations of invoice fraud and illegal labor activities.

Alphabet ($GOOG$) decreased by 0.52%, despite the overall surge in quantum computing stocks. Google's stock hit a new high, driven by advancements in AI-driven content generation tools.

Meta Platforms ($META$) declined by 0.77% even as Truist Securities maintained a 'Buy' rating and raised the price target to $700 per share, indicating a positive outlook for the company's growth.

Broadcom ($AVGO$) experienced a significant drop of 3.91%, despite the record high of its shares. The decline was attributed to broader market trends and sector-specific challenges.

Pfizer ($PFE$) rose by 4.67% after releasing its 2025 full-year guidance, projecting revenues between $61 billion and $64 billion and adjusted diluted EPS between $2.80 and $3.00. The company expects COVID-19 vaccine and drug sales to remain consistent with 2024 levels.